European Journal of Medicinal Plants

Background: Polyherbal decoctions (Kwatha) occupy a central place in classical Ayurvedic therapeutics, combining multiple drugs to achieve a composite pharmacodynamic effect. Asanadi Kwatha is a classical twenty-four-drug polyherbal formulation indicated principally in Prameha (a broad classical category overlapping with, but not synonymous with, diabetes mellitus), along with disorders of Rakta (blood tissue) and skin.

Aims: The aim was to critically review the Ayurvedic pharmacodynamic (Rasa–Guna–Virya–Vipaka–Doshaghnata) profile, phytochemical constituents and pharmacological activities of Asanadi Kwatha's constituents and to evaluate the strength and gaps of evidence at both constituent and formulation levels.

Methodology: A narrative, critically appraised review was conducted using classical Dravyaguna literature and peer-reviewed databases (PubMed, Scopus-indexed journals, Web of Science where accessible, Google Scholar and ScienceDirect); searches used accepted botanical names with phytochemical and pharmacological terms.

Results: The constituents collectively show a broad pharmacological profile, with evidence supporting antidiabetic, antioxidant, anti-inflammatory, hypolipidemic, hepatoprotective, cardioprotective and antimicrobial activities, most strongly for Arjuna (cardioprotective), Gymnema sylvestre and Acacia catechu (antidiabetic), and several tannin-rich barks (antioxidant, hepatoprotective). Evidence quality is uneven, from clinical trials for a few constituents to purely in vitro or genus-level data for others. Direct pharmacological evidence on the complete Asanadi Kwatha preparation described here is essentially absent; the only formulation-level datum identified concerns a differently-sourced, similarly-named preparation and cannot be directly extrapolated.

Conclusion: Asanadi Kwatha shows a plausible, multidimensional constituent-level pharmacological rationale consistent with its classical Kapha–Pitta hara, Kashaya-dominant profile, but formulation-level pharmacological and clinical validation remains largely absent and is required before therapeutic claims for the complete decoction can be substantiated.